FDA Approves First Treatment for Adult Onset Still’s Disease
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).

• Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.

• AOSD is a rare and serious autoinflammatory disease of unknown origin. Characteristics of AOSD have considerable overlap with Systemic Juvenile Idiopathic Arthritis (SJIA), which includes fever, arthritis, rash and elevated markers for inflammation.

• The role of interleukin-1 (IL-1) is well-established in AOSD and SJIA. Ilaris works by blocking the effects of IL-1 and suppressing inflammation in patients with this autoinflammatory disorder.

• Common side effects: infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions. Patients are advised not to receive live vaccinations during treatment.

• The approval of Ilaris was granted to Novartis Pharmaceuticals Corp.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-adult-onset-stills-disease-severe-and-rare-disease
Dr. T●●●●z H●●●●●●i and 1 others like this1 share
Like
Comment
Share